Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
Proscia'a digital pathology platform allows pathologists to view, manage, and analyze whole-slide images and is interoperable with laboratory information systems.
The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.
The company is providing DNA/RNA extraction kits, viral RNA isolation platforms, workstations, and kits for detecting nucleic acids from the coronavirus to the lab.